Cargando…

Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study

Probiotic supplementation has been part of the discussion on methods to enhance humoral immunity. Administration of Bifidobacterium bifidum OLB6378 (OLB6378) reduced the incidence of late-onset sepsis in infants. In this non-randomized study, we aimed to determine the effect of administration of liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Katsunori, Tsukahara, Takamitsu, Yanagi, Takahide, Nakahara, Sayuri, Furukawa, Ouki, Tsutsui, Hidemi, Koshida, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372858/
https://www.ncbi.nlm.nih.gov/pubmed/28245626
http://dx.doi.org/10.3390/nu9030195
_version_ 1782518705010245632
author Tanaka, Katsunori
Tsukahara, Takamitsu
Yanagi, Takahide
Nakahara, Sayuri
Furukawa, Ouki
Tsutsui, Hidemi
Koshida, Shigeki
author_facet Tanaka, Katsunori
Tsukahara, Takamitsu
Yanagi, Takahide
Nakahara, Sayuri
Furukawa, Ouki
Tsutsui, Hidemi
Koshida, Shigeki
author_sort Tanaka, Katsunori
collection PubMed
description Probiotic supplementation has been part of the discussion on methods to enhance humoral immunity. Administration of Bifidobacterium bifidum OLB6378 (OLB6378) reduced the incidence of late-onset sepsis in infants. In this non-randomized study, we aimed to determine the effect of administration of live OLB6378 on infants’ humoral immunity. Secondly, we tried to elucidate whether similar effects would be observed with administration of non-live OLB6378. Low birth weight (LBW) infants weighing 1500–2500 g were divided into three groups: Group N (no intervention), Group L (administered live OLB6378 concentrate), and Group H (administered non-live OLB6378 concentrate). The interventions were started within 48 h after birth and continued until six months of age. Serum immunoglobulin G (IgG) levels (IgG at one month/IgG at birth) were significantly higher in Group L than in Group N (p < 0.01). Group H exhibited significantly higher serum IgG levels (p < 0.01) at one month of age and significantly higher intestinal secretory immunoglobulin A (SIgA) levels (p < 0.05) at one and two months of age than Group N. No difference was observed in the mortality or morbidity between groups. Thus, OLB6378 administration in LBW infants enhanced humoral immunity, and non-live OLB6378, which is more useful as a food ingredient, showed a more marked effect than the viable bacteria.
format Online
Article
Text
id pubmed-5372858
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53728582017-04-05 Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study Tanaka, Katsunori Tsukahara, Takamitsu Yanagi, Takahide Nakahara, Sayuri Furukawa, Ouki Tsutsui, Hidemi Koshida, Shigeki Nutrients Article Probiotic supplementation has been part of the discussion on methods to enhance humoral immunity. Administration of Bifidobacterium bifidum OLB6378 (OLB6378) reduced the incidence of late-onset sepsis in infants. In this non-randomized study, we aimed to determine the effect of administration of live OLB6378 on infants’ humoral immunity. Secondly, we tried to elucidate whether similar effects would be observed with administration of non-live OLB6378. Low birth weight (LBW) infants weighing 1500–2500 g were divided into three groups: Group N (no intervention), Group L (administered live OLB6378 concentrate), and Group H (administered non-live OLB6378 concentrate). The interventions were started within 48 h after birth and continued until six months of age. Serum immunoglobulin G (IgG) levels (IgG at one month/IgG at birth) were significantly higher in Group L than in Group N (p < 0.01). Group H exhibited significantly higher serum IgG levels (p < 0.01) at one month of age and significantly higher intestinal secretory immunoglobulin A (SIgA) levels (p < 0.05) at one and two months of age than Group N. No difference was observed in the mortality or morbidity between groups. Thus, OLB6378 administration in LBW infants enhanced humoral immunity, and non-live OLB6378, which is more useful as a food ingredient, showed a more marked effect than the viable bacteria. MDPI 2017-02-26 /pmc/articles/PMC5372858/ /pubmed/28245626 http://dx.doi.org/10.3390/nu9030195 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tanaka, Katsunori
Tsukahara, Takamitsu
Yanagi, Takahide
Nakahara, Sayuri
Furukawa, Ouki
Tsutsui, Hidemi
Koshida, Shigeki
Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title_full Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title_fullStr Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title_full_unstemmed Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title_short Bifidobacterium bifidum OLB6378 Simultaneously Enhances Systemic and Mucosal Humoral Immunity in Low Birth Weight Infants: A Non-Randomized Study
title_sort bifidobacterium bifidum olb6378 simultaneously enhances systemic and mucosal humoral immunity in low birth weight infants: a non-randomized study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372858/
https://www.ncbi.nlm.nih.gov/pubmed/28245626
http://dx.doi.org/10.3390/nu9030195
work_keys_str_mv AT tanakakatsunori bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT tsukaharatakamitsu bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT yanagitakahide bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT nakaharasayuri bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT furukawaouki bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT tsutsuihidemi bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy
AT koshidashigeki bifidobacteriumbifidumolb6378simultaneouslyenhancessystemicandmucosalhumoralimmunityinlowbirthweightinfantsanonrandomizedstudy